National Trends in Smoking Cessation Medication Prescriptions for Smokers With Chronic Obstructive Pulmonary Disease in the United States, 2007-2012.
- Author:
Min Ji KWAK
1
;
Jongoh KIM
;
Viraj BHISE
;
Tong Han CHUNG
;
Gabriela Sanchez PETITTO
Author Information
- Publication Type:Brief Communication
- Keywords: Chronic obstructive pulmonary disease; Smoking cessation; Varenicline; Bupropion; Tobacco use cessation products; Nicotine
- MeSH: Bupropion; Comorbidity; Continental Population Groups; Depression; Drug Therapy; Health Care Surveys; Hispanic Americans; Humans; Insurance; Logistic Models; Mortality; Nicotine; Prescriptions*; Pulmonary Disease, Chronic Obstructive*; Retrospective Studies; Smoke*; Smoking Cessation*; Smoking*; Tobacco Use Cessation Products; United States*; Varenicline
- From:Journal of Preventive Medicine and Public Health 2018;51(5):257-262
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVES: Smoking cessation decreases morbidity and mortality due to chronic obstructive pulmonary disease (COPD). Pharmacotherapy for smoking cessation is highly effective. However, the optimal prescription rate of smoking cessation medications among smokers with COPD has not been systemically studied. The purpose of this study was to estimate the national prescription rates of smoking cessation medications among smokers with COPD and to examine any disparities therein. METHODS: We conducted a retrospective study using National Ambulatory Medical Care Survey data from 2007 to 2012. We estimated the national prescription rate for any smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy) each year. Multiple survey logistic regression was performed to characterize the effects of demographic variables and comorbidities on prescriptions. RESULTS: The average prescription rate of any smoking cessation medication over 5 years was 3.64%. The prescription rate declined each year, except for a slight increase in 2012: 9.91% in 2007, 4.47% in 2008, 2.42% in 2009, 1.88% in 2010, 1.46% in 2011, and 3.67% in 2012. Hispanic race and depression were associated with higher prescription rates (odds ratio [OR], 5.15; 95% confidence interval [CI], 1.59 to 16.67 and OR, 2.64; 95% CI, 1.26 to 5.51, respectively). There were no significant differences according to insurance, location of the physician, or other comorbidities. The high OR among Hispanic population and those with depression was driven by the high prescription rate of bupropion. CONCLUSIONS: The prescription rate of smoking cessation medications among smokers with COPD remained low throughout the study period. Further studies are necessary to identify barriers and to develop strategies to overcome them.
